White Paper: The Benefit Assessment of New Metastatic Breast Cancer (Mbc) Treatments
EUSOMA partecipates in a multi-stakeholder collaboration in MBC aiming to editing a white paper on “The Benefit Assessment of New Metastatic Breast Cancer (Mbc) Treatments”.
Metastatic Breast Cancer (MBC) places a major humanistic and economic burden on patients and their caregivers, along with issues of equity in access to quality care. It is recognised that various health systems are facing difficult prioritisation decisions when introducing new MBC treatments. The introduction of new MBC treatments may be hindered by several elements including the availability of relevant evidence of value. Therefore, in a multi-stakeholder collaboration, this White Paper aims to place MBC on the agenda of national policy makers and provide policy recommendations and solutions to current challenges in decision-making processes within access to MBC care and treatment in several countries from Europe, Australia and Canada.
The focus of this White Paper is two-fold; i) the challenges in the overall benefit assessment of new MBC treatments, ii) the role of multi-stakeholder collaboration in MBC decision-making.
It is proposed that decision-makers should begin to consistently consider MBC patient needs, patient relevant outcomes and attributes in the overall benefit assessment of MBC treatments.
The two over-arching policy recommendations are:
• Include MBC-specific patient priorities and outcomes in the overall benefit assessment of new MBC treatments
• Enhance multi-stakeholder collaboration in order to improve MBC patient outcomes
The project coordinated by ICON plc., with the financial support of Eli Lilly & Company (Lilly), has been closed in March 2019 and is available on lillyPadEU website https://lillypad.eu/